公开(公告)号：US20240335592A1

公开(公告)日：2024-10-10

申请号：US18743016

申请日：2024-06-13

Applicant: Vanderbilt University

Inventor： Scott A. Guelcher ,  Sichang Lu ,  Madison A.P. McGough ,  Katarzyna J. Zienkiewicz

IPC: A61L27/48 ,  A61L27/10 ,  A61L27/18 ,  A61L27/20 ,  A61L27/26 ,  A61L27/46 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  C04B26/16 ,  C04B111/00 ,  C08G18/10 ,  C08G18/38 ,  C08G18/48 ,  C08G18/77 ,  C08G18/80

CPC classification number: A61L27/48 ,  A61L27/10 ,  A61L27/18 ,  A61L27/20 ,  A61L27/26 ,  A61L27/46 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  C04B26/16 ,  C08G18/10 ,  C08G18/3868 ,  C08G18/4833 ,  C08G18/771 ,  C08G18/8061 ,  A01K2207/20 ,  A61L2300/404 ,  A61L2300/412 ,  A61L2300/604 ,  A61L2400/06 ,  A61L2400/12 ,  A61L2430/02 ,  C04B2111/00836

Abstract: A hybrid composite and method for producing a polymer network are provided. The hybrid composite includes nanocrystalline hydroxyapatite (nHA) and polyurethane. The method for producing a polymer network includes reacting nanocrystalline hydroxyapatite (nHA) particles with lysine derived triisocyanate (LTI) to form a nHA/LTI hybrid prepolymer and reacting the prepolymer with a thioketal (TK) diol to form a nHA/poly(thioketal urethane) (PTKUR) hybrid polymer network.

公开(公告)号：US20240238485A1

公开(公告)日：2024-07-18

申请号：US18621669

申请日：2024-03-29

Applicant: Massachusetts Institute of Technology ,  The General Hospital Corporation

Inventor： Laura Indolfi ,  Elazer R. Edelman ,  Robert S. Langer ,  Jeffrey W. Clark ,  David T. Ting ,  Cristina Rosa Annamaria Ferrone ,  Matteo Ligorio

IPC: A61L31/10 ,  A61F2/04 ,  A61F2/915 ,  A61K9/00 ,  A61K9/70 ,  A61K31/337 ,  A61K47/34 ,  A61L31/14 ,  A61L31/16

CPC classification number: A61L31/10 ,  A61K9/0024 ,  A61K9/0034 ,  A61K9/7007 ,  A61K31/337 ,  A61K47/34 ,  A61L31/148 ,  A61L31/16 ,  A61F2002/041 ,  A61F2/915 ,  A61F2230/0021 ,  A61L2300/416 ,  A61L2300/604 ,  A61L2300/606 ,  A61L2420/06

Abstract: Drug-eluting devices and methods for the treatment of tumors of the pancreas, biliary system, gallbladder, liver, small bowel, or colon, are provided. Methods include deploying a drug-eluting device having a film which includes a mixture of a degradable polymer and a chemotherapeutic drug, wherein the film has a thickness from about 2 μm to about 1000 μm, into a tissue site and releasing a therapeutically effective amount of the chemotherapeutic drug from the film to treat the tumor, wherein the release of the therapeutically effective amount of the drug from the film is controlled by in vivo degradation of the polymer at the tissue site.

公开(公告)号：US11969528B2

公开(公告)日：2024-04-30

申请号：US16472779

申请日：2017-10-30

Applicant: SINO MEDICAL SCIENCES TECHNOLOGY INC.

Inventor： Jianhua Sun ,  Christophe Bureau ,  Wenbin Cai ,  Tianzhu Li ,  Xiaoran Kang

IPC: A61L31/16 ,  A61F2/82 ,  A61K31/337 ,  A61K31/436 ,  A61L31/10 ,  A61L33/18 ,  B05D1/00 ,  B05D1/02 ,  B05D3/04

CPC classification number: A61L31/16 ,  A61F2/82 ,  A61K31/337 ,  A61K31/436 ,  A61L31/10 ,  A61L33/18 ,  B05D1/002 ,  B05D1/02 ,  B05D3/0486 ,  A61L2300/256 ,  A61L2300/258 ,  A61L2300/412 ,  A61L2300/416 ,  A61L2300/604 ,  A61L2420/08

Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

公开(公告)号：US20190247538A1

公开(公告)日：2019-08-15

申请号：US16391195

申请日：2019-04-22

Applicant: Silver Bullet Therapeutics, Inc.

Inventor： Houdin DEHNAD ,  Paul E. CHIRICO ,  Bohdan Wolodymyr CHOPKO ,  John BARR ,  Robert Vincent McCORMICK ,  Julie LUCERO ,  Jason A. JEGGE

IPC: A61L27/18 ,  A61L31/16 ,  A01N25/34 ,  A61L31/08 ,  A61L27/54 ,  A61L29/10 ,  A61L29/16 ,  A61K33/24 ,  A61K33/30 ,  A61K33/38 ,  A61L31/14 ,  C08L67/04 ,  A61L27/30 ,  A61L27/58 ,  A61L31/06

CPC classification number: A61L27/18 ,  A01N25/34 ,  A61K33/24 ,  A61K33/30 ,  A61K33/38 ,  A61L27/306 ,  A61L27/54 ,  A61L27/58 ,  A61L29/106 ,  A61L29/16 ,  A61L31/06 ,  A61L31/088 ,  A61L31/148 ,  A61L31/16 ,  A61L2300/102 ,  A61L2300/104 ,  A61L2300/404 ,  A61L2300/602 ,  A61L2300/604 ,  A61L2300/606 ,  A61L2400/18 ,  A61L2420/06 ,  C08L67/04 ,  A01N59/16 ,  A01N59/20 ,  A61K2300/00

Abstract: Antimicrobial metal ion coatings and implants including them. In particular, described herein are coatings including an anodic metal (e.g., silver and/or zinc and/or copper) that is co-deposited with a cathodic metal (e.g., palladium, platinum, gold, molybdenum, titanium, iridium, osmium, rhodium, manganese, niobium or rhenium) on a substrate so that the anodic metal is galvanically released as antimicrobial ions when the apparatus is exposed to a bodily fluid. The anodic metal may be at least about 25 percent by volume of the coating, resulting in a network of anodic metal with less than 20% of the anodic metal in the coating fully encapsulated by cathodic metal. The implant may be configured as an implant such as a bone-screw or intramedullary rod-like body configured to receive a treatment cartridge having a coating as described.

公开(公告)号：US20190192727A1

公开(公告)日：2019-06-27

申请号：US16289469

申请日：2019-02-28

Applicant: MediBeacon Inc.

Inventor： Bob O. Basore ,  William L. Neumann ,  Richard B. Dorshow ,  Raghavan Rajagopalan

IPC: A61L24/10 ,  A61L24/04 ,  A61L24/00

CPC classification number: A61L24/102 ,  A61L24/001 ,  A61L24/0015 ,  A61L24/0042 ,  A61L24/046 ,  A61L24/106 ,  A61L24/108 ,  A61L2300/418 ,  A61L2300/442 ,  A61L2300/604 ,  A61L2400/04 ,  A61L2430/20 ,  A61L2430/34

Abstract: The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.

公开(公告)号：US20190125537A1

公开(公告)日：2019-05-02

申请号：US16173372

申请日：2018-10-29

Applicant: PURDUE RESEARCH FOUNDATION

Inventor： Thomas J. WEBSTER ,  Venu PERLA

IPC: A61F2/30 ,  C25D11/02 ,  A61K9/00 ,  A61B17/08 ,  A61L27/32 ,  A61L27/50 ,  C25D5/34 ,  A61L31/02 ,  A61L31/16 ,  A61L27/04 ,  A61L27/54 ,  A61L27/34 ,  A61L27/56

CPC classification number: A61F2/30771 ,  A61B17/08 ,  A61F2/30 ,  A61F2002/30011 ,  A61F2002/30062 ,  A61F2002/30064 ,  A61F2002/3084 ,  A61F2002/3092 ,  A61F2002/30929 ,  A61F2002/3093 ,  A61F2002/30968 ,  A61F2310/00023 ,  A61F2310/0097 ,  A61F2310/00982 ,  A61K9/0024 ,  A61K9/0092 ,  A61L27/04 ,  A61L27/32 ,  A61L27/34 ,  A61L27/50 ,  A61L27/54 ,  A61L27/56 ,  A61L31/022 ,  A61L31/16 ,  A61L2300/414 ,  A61L2300/604 ,  A61L2300/624 ,  A61L2400/12 ,  A61L2400/18 ,  A61L2430/02 ,  C25D5/34 ,  C25D11/02 ,  Y10T428/24355

Abstract: One embodiment of the present invention is directed to compositions and methods for enhancing attachment of soft tissues to a metal prosthetic device. In one embodiment a construct is provided comprising a metal implant having a porous metal region, wherein said porous region exhibits a nano-textured surface.

公开(公告)号：US20180243472A1

公开(公告)日：2018-08-30

申请号：US15963337

申请日：2018-04-26

Applicant: Sofradim Production

Inventor： Sébastien Ladet ,  Julien Claret

IPC: A61L27/20 ,  A61L27/24 ,  A61L27/54 ,  A61K47/36 ,  A61K9/00 ,  A61L27/56

CPC classification number: A61L27/20 ,  A61K9/0024 ,  A61K45/00 ,  A61K47/36 ,  A61L27/24 ,  A61L27/48 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  A61L2300/604 ,  A61L2430/00 ,  B05D5/00 ,  B32B37/24 ,  Y10T29/49947 ,  Y10T156/10 ,  C08L5/08

Abstract: Mono- and multi-layered implants include at least one porous layer made from a freeze dried aqueous solution containing chitosan, the solution having a pH of less than about 5.

公开(公告)号：US10058641B2

公开(公告)日：2018-08-28

申请号：US15091473

申请日：2016-04-05

Applicant: Abbott Laboratories

Inventor： Karl W. Mollison ,  Angela M. LeCaptain ,  Sandra E. Burke ,  Keith R. Cromack ,  Peter J. Tarcha ,  Yen-Chih J. Chen ,  John L. Toner

IPC: A61L31/16 ,  A61L27/54 ,  A61L31/14 ,  A61L27/34 ,  A61L29/08 ,  A61L29/16 ,  A61L31/10 ,  C07D498/18

CPC classification number: A61L31/16 ,  A61L27/34 ,  A61L27/54 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/148 ,  A61L2300/41 ,  A61L2300/416 ,  A61L2300/426 ,  A61L2300/604 ,  A61L2300/606 ,  C07D498/18

Abstract: A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to drugs of Formula (I). The drugs of Formula (I) can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

公开(公告)号：US10034966B2

公开(公告)日：2018-07-31

申请号：US15599634

申请日：2017-05-19

Applicant: Carnegie Mellon University

Inventor： Christopher J. Bettinger ,  Michael Bruce Horowitz

IPC: A61L29/08 ,  A61L31/16 ,  A61L31/06 ,  A61L31/10 ,  A61L29/16 ,  A61M25/00 ,  A61K31/352 ,  A61L29/14 ,  A61B17/12

CPC classification number: A61L29/085 ,  A61B17/12031 ,  A61B17/12113 ,  A61B17/12145 ,  A61B17/1215 ,  A61K31/352 ,  A61L29/148 ,  A61L29/16 ,  A61L31/06 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/252 ,  A61L2300/602 ,  A61L2300/604 ,  A61L2420/04 ,  A61L2420/08 ,  A61L2430/36 ,  A61M25/0045 ,  C08L67/04

Abstract: A method is described herein for the treatment of intracranial aneurysms. The method comprises inserting into an aneurysm an embolism coil coated with a polymeric coating comprising a genipin, such as genipin or a derivative thereof, thereby increasing the stability of clots within the aneurysm. According to one example, the coating is a poly(L-lactide-co-glycolide) (PLGA) is used to release genipin to crosslink fibrin clots thereby creating more stable occlusions. Increased clotting can improve segregation of the weakened portion of the blood vessel from the rest of the vasculature and reduce the risk of recurrence.

公开(公告)号：US10034956B2

公开(公告)日：2018-07-31

申请号：US15283374

申请日：2016-10-01

Applicant: BVW Holding AG

Inventor： Lukas Bluecher ,  Michael Milbocker

IPC: A61L26/00 ,  A61K47/32 ,  C08G18/48 ,  C08G18/64 ,  C08G18/73 ,  C08G18/75 ,  C08G18/76 ,  C08G18/10 ,  C08G18/12 ,  C08G18/24 ,  C08G18/28 ,  C08G18/40 ,  C08G18/42 ,  C08G18/44 ,  A61L27/18 ,  A61L27/52 ,  A61L27/54 ,  A61K9/06 ,  A61K36/324 ,  C08G18/32 ,  C08G18/65 ,  C08G83/00

CPC classification number: A61L26/0019 ,  A61K9/06 ,  A61K36/324 ,  A61K47/32 ,  A61L26/0023 ,  A61L26/0066 ,  A61L26/008 ,  A61L26/009 ,  A61L27/18 ,  A61L27/52 ,  A61L27/54 ,  A61L2300/30 ,  A61L2300/412 ,  A61L2300/604 ,  A61L2430/34 ,  C08G18/10 ,  C08G18/12 ,  C08G18/244 ,  C08G18/246 ,  C08G18/2825 ,  C08G18/3206 ,  C08G18/4018 ,  C08G18/4277 ,  C08G18/428 ,  C08G18/44 ,  C08G18/48 ,  C08G18/4825 ,  C08G18/4833 ,  C08G18/4837 ,  C08G18/4854 ,  C08G18/4887 ,  C08G18/6484 ,  C08G18/65 ,  C08G18/73 ,  C08G18/755 ,  C08G18/7621 ,  C08G83/003 ,  C08G2210/00 ,  C08G2230/00 ,  C08G18/348 ,  C08G18/3234

Abstract: Disclosed are hydrogels polymerized with a biofunctional moiety, biodegradable and permanent, designed to be implantable in a mammalian body and intended to block or mitigate the formation of tissue adhesions. The hydrogels of the present invention are characterized by comprising four structural elements: a) a polymeric backbone which defines the overall polymeric morphology, b) linkage groups, c) side chains, and d) biofunctional end groups. The hydrophobicity of the various structural elements are chosen to reduce tissue adhesion and enhance the biofunctional aspect of the end groups. The morphology of these polymers are typically of high molecular weight and have shape to encourage entanglement. Useful structures include branching chains, comb or brush, and dendritic morphologies.